Life Sciences INDUSTRIES

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Recognized as a leading life sciences practice, WilmerHale has represented life sciences clients across the United States and Europe for more than four decades. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other institutions in the space, including venture capitalists, investment banks, universities and others, we understand the business of our life sciences clients and the changing regulatory and competitive demands they face.


Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)


Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)


WilmerHale's Life Sciences Practice has extraordinary range, and the majority of our lawyers devote a significant portion of their practice to areas critical to life sciences clients. The firm's multi-disciplinary teams work seamlessly to handle a broad range of matters for clients, including corporate finance, licensing and strategic alliances, litigation, mergers and acquisitions, intellectual property, Food and Drug Administration (FDA), competition and other regulatory matters, and securities fraud. Our lawyers advise on venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protect clients' innovations through patent prosecution and portfolio development; and defend their interests in enterprise-critical patent litigation. We also represent life sciences clients in dealings with the United States and other governments on regulatory matters, including issues before the FDA and other agencies, merger clearance and enforcement actions, and public policy and strategy. Read about some of our recent life sciences transactions.

Our Life Sciences Practice includes corporate lawyers who have helped thousands of entrepreneurs successfully launch their businesses; raise billions in financing; and take their companies to sale, the public markets and/or through drug commercialization. We have a longstanding tradition of representing emerging companies and entrepreneurs across industries, and routinely offer the strategic advice and sharp business perspectives that are critical to our clients' success. Learn about our startup practice at

Publications & News


March 16, 2018

WilmerHale Recognized for Outstanding International Lawyers and Practices in Chambers Global 2018

In the 2018 edition of Chambers Global, 33 WilmerHale lawyers were named among “The World's Leading Lawyers for Business."

March 15, 2018

WilmerHale Represents Behavioral Biometrics Leader BioCatch in Closing $30M New Investment

BioCatch, a global leader in behavioral biometrics, announced that it has closed a $30 million financing round, cementing its growth plan and vision to redefine digital identity and enable renewed trust in online interactions.

March 14, 2018

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

March 8, 2018

The #MeToo Movement: The Critical Role of the Board in Preparing for, Responding to and Avoiding Sexual Misconduct Allegations

As the #MeToo movement gains momentum, companies in nearly every major industry are dealing with allegations of gender discrimination, sexual harassment or even sexual assault—including allegations of widespread misconduct and inappropriate behavior within the upper echelons of the corporate structure.

March 8, 2018

New Partnership Audit Rules in Effect; Partnerships and LLCs Should Consider Changes

A new “centralized partnership audit regime” is now in effect for partnerships, including limited liability companies (LLCs) that are treated as partnerships for tax purposes (which we refer to collectively as “partnerships”). The new regime, which was enacted by the Bipartisan Budget Act of 2015, applies to all partnerships (domestic and foreign) for taxable years beginning after December 31, 2017.

March 1, 2018

WilmerHale Reps Eko Devices in $5M Series A Round Led by ARTIS Ventures

On February 28, 2018, Eko Devices, a leader in acoustic cardiac monitoring, announced that it closed $5 million in Series A funding to grow its commercial team and to expand clinical studies on the use of its platform for valvular heart disease screening and heart failure monitoring.

February 28, 2018

WilmerHale Represents Generation Bio in $100M Series B Financing

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing.

January 30, 2018

WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

Ocular Therapeutix™, Inc. announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share.

January 26, 2018

WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

Karyopharm Therapeutics Inc. announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.


  • Chambers USA: America's Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007-2017 with sources saying our attorneys are "responsive, efficient and very technically sophisticated." 
  • Chambers Global - Recognized WilmerHale as a leader in life sciences from 2013-2017, and noted that sources appreciate the firm's “client service, commerciality and value for money.”
  • Chambers Europe - Recognized WilmerHale as a leader in life sciences in Germany in its 2013-2017 editions.
  • In Vivo – Named Regeneron's novel deal with Decibel Therapeutics, represented by WilmerHale, as the Top Alliance 2017 Deal of the Year.
  • Lake Whillans - The Life Sciences Law Firm Index included WilmerHale among the top three best life sciences law firms (2016, 2017), as the top firm for startup work (2017), among the top 10 deal firms (2017), the top two patent law firms (2016) and top 10 firms for thought leadership (2016).
  • Law360 - Named WilmerHale a Technology Practice Group of the Year for 2016 and a Life Sciences Practice Group of the Year for 2013 in its annual rankings, which recognize firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year.
  • LMG Life Sciences - Named WilmerHale the Life Cycle Firm of the Year in 2017 and awarded the firm one of five Finance and Transactional Impact Cases of the Year for counseling Editas Medicine in its licensing and collaboration with Allergan. LMG ranked the firm in its 2012-2017 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and previously named WilmerHale a Life Cycle Firm in 2012-2015. In 2013, WilmerHale was named the winner of the Canadian Impact Deals of the Year award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013-2016. In 2013, 2016 and 2017, WilmerHale was named the "Patent Contentious Firm of the Year" and in 2013, the "Pharmaceutical IP Litigation Firm of the Year."
  • The American Lawyer - Placed WilmerHale on its 2016 "A-List" as one of the United States' leading law firms, marking the 13th year the firm received that recognition.
  • The American Lawyer - Named WilmerHale the 2014 IP Litigation Department of the Year and a finalist for its 2016 IP Litigation Department of the Year. The firm has been named a winner twice and a finalist six times since the contests launch in 2004.
  • The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharma industry in its BTI Power Rankings 2016 report.
  • The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013-2017 with sources saying the firm "brings a great deal of experience to any situation" and "has access to additional expertise/resources to help solve any problem."
  • The National Law Journal - Named WilmerHale to its 2012-2015 Intellectual Property Hot List, which honors firms that demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® - Recognized the firm in its 2014-2017 "Best Law Firms" lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, patent law, securities and venture capital law. In 2017, WilmerHale received first-tier metropolitan rankings in Boston intellectual property litigation, patent law, technology law and venture capital law; in Colorado for intellectual property litigation; in New York for biotechnology law and corporate law; in San Jose for patent litigation; and in Washington DC for intellectual property litigation.